Doctolib vs Doximity

Nvidia invests in Doctolib, Pigment, Genesis AI, Entalpic

European tech startups raised €15.8 billion in September, nearly five times August's €3.2 billion, with the UK attracting the largest share (46%). Mega-deals included Mistral's €3 billion Series D and Nscale's $3.36 billion convertible notes; even excluding these, funding tripled month-over-month. Nvidia continued its European expansion by announcing minority investments in four French startups (Doctolib, Genesis AI, Pigment, Entalpic) and five UK startups (Boltz, Foresight, Hiverge, Prima Mente, Riverlane), as part of nearly €9 billion in European commitments. CEO Jensen Huang also announced a $250 million compute donation to UK AI safety and research. Critics question circular financing, while Huang advocates continued dialogue with Chinese AI firms. These moves follow Nvidia's recent agreement to acquire Hugging Face for about $12.9 billion.

• European startups raised €15.8 billion in September, nearly five times August's €3.2 billion.
• Nvidia announced minority investments in four French (Doctolib, Genesis AI, Pigment, Entalpic) and five UK (Boltz, Foresight, Hiverge, Prima Mente, Riverlane) startups, with total European commitment near €9 billion.
• Mistral raised €3 billion in Series D at a valuation over €21 billion, the largest equity round for a European tech company.

Nvidia Invests in Four French Tech Companies

Nvidia has announced investments in four French technology companies during Jensen Huang's visit to Paris. The companies are Doctolib, a healthcare appointment platform; Genesis AI, a robotics startup; Pigment, a financial planning software maker; and Entalpic, a materials research startup. The deals are minority stakes, but the specific amounts and equity sizes were not disclosed. Nvidia's investment in Doctolib is intended to support its development of AI agents and a digital health companion. This move is part of Nvidia's broader commitment of nearly $10 billion to Europe's tech ecosystem, with plans to announce an additional $2 billion in European deals within a week. The investments have drawn criticism over potential circular financing, where AI firms use the funds to buy Nvidia chips, but Huang rejects these claims.

• Nvidia invests in Doctolib, Genesis AI, Pigment, and Entalpic.
• The investments are minority stakes; amounts undisclosed.
• Investment in Doctolib supports its AI agent and health companion work.

Doximity Faces Securities Fraud Class Action Lawsuit

Schall, Brown & Schwartz LLP (SBS) has announced a class action lawsuit against Doximity, Inc. (NYSE: DOCS) for alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The complaint claims Doximity made false and misleading statements, overstating the positive impact of its Newsfeed product on revenue growth and misleading investors about its advertising delivery methods, which included banner ads and newsletters. The class period is from August 8, 2024, to May 13, 2026, with a deadline of November 16, 2026, for investors to seek lead plaintiff appointment. Investors who purchased shares during this period may be eligible for recovery.

• SBS files class action lawsuit against Doximity for securities fraud violations.
• Class period: August 8, 2024 to May 13, 2026.
• Deadline for lead plaintiff appointment: November 16, 2026.

Novant Health Partners with Doximity to Bring Evidence-Based Clinical AI Into Epic

Doximity announces new partnerships with Novant Health and Penn Highlands Healthcare to deploy its Clinical AI Suite, and releases the 2026 Physician Compensation Report highlighting AI fluency as a career advantage.

Penn Highlands Healthcare Partners with Doximity to Launch System-Wide Clinical AI Suite

Doximity announces a partnership with Penn Highlands Healthcare to deploy its Clinical AI Suite system-wide.